Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

X

William Newton

12 Oct 2021

News

pHOXBIO eyes UK study of preventive Covid-19 nasal spray by year’s end

12 Oct 2021

30 Sep 2021

Analysis

Sage and Biogen’s depression drug iffy on efficacy despite dosing, safety upside

30 Sep 2021

22 Sep 2021

Analysis

Merck and Ridgeback’s molnupiravir rollout difficult to map in uncertain Covid-19 landscape

22 Sep 2021

20 Sep 2021

News

Oral molnupiravir has at least 350 patients left to recruit in Phase III Covid-19 trial

20 Sep 2021

27 Aug 2021

Analysis

Retrotope eyes $100m raise for neurodegenerative disease platform

27 Aug 2021

23 Aug 2021

Analysis

The incomplete safety data on Aduhelm’s brain swelling side effect

23 Aug 2021

04 Aug 2021

Analysis

BioMarin’s growth-accelerating drug for dwarfism will face scrutiny from European payers

04 Aug 2021

03 Aug 2021

Analysis

Medicare’s National Coverage Determination could boost chances of limited Aduhelm coverage despite backlash

03 Aug 2021

29 Jul 2021

Comment

Aerie’s eye drop for dry eyes has promising target but trial design a possible spoiler

29 Jul 2021

07 Jul 2021

Comment

LoA Update: Akari’s Phase III paroxysmal nocturnal hemoglobinuria asset has six-point fall in regulatory approval chances after trial termination

07 Jul 2021